“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
Mumbai, August 7, 2015:Pharma Major Lupin Limited (Lupin) today announced the
opening of its new Center of Excellence for Inhalation Research in Coral Springs, Florida. Local and state leaders,
including Florida Lieutenant Governor Carlos Lopez-Cantera, Florida Department of Economic Opportunity
Director Jesse Panuccio, and Mayor Skip Campbell, were on site to celebrate the opening of Lupin’s new facility
with a ribbon cutting ceremony. Bringing 45 highly skilled positions to Broward County, Lupin’s South Florida
expansion recognizes the steady growth of Florida’s life sciences industry and the economic potential it holds for
the state. Lupin’s new facility will focus on the research and development of inhalation products for the
treatment of asthma, allergic rhinitis, chronic obstructive pulmonary diseases and other lung diseases.
"We are delighted to be making our mark in South Florida," said Vinita Gupta, CEO, Lupin Limited. "With the
talent and resources this state provides, our Coral Springs expansion will further strengthen our ability to bring
quality, affordable pharmaceuticals to patients in the United States and other key markets globally. The new
inhalation research and development facility is a significant step forward in our journey to emerge as a global
specialty pharmaceutical player."
"Lupin’s Coral Springs expansion further reinforces Florida’s standing as the number one place to do business,"
said Florida Lt. Governor Carlos Lopez-Cantera. "The opening of this facility is a testament to the strength of
Florida’s life sciences industry and the diverse and talented workforce who call this state home. We welcome
Lupin to the Sunshine State and look forward to the incredible research and therapies that are developed as a
result of their presence in Florida."
Lupin’s Coral Springs facility was made possible through collaboration among Enterprise Florida, the Florida
Department of Economic Opportunity, CareerSource Florida, Broward County and the Greater Fort Lauderdale
Florida Department of Economic Opportunity Executive Director Jesse Panuccio said, "The official opening of
Lupin Inc. is great news for the City of Coral Springs and the Florida economy. The Scott administration’s pro-
growth policies are fostering Florida’s emergent life sciences sector, as companies like Lupin continue to create
high-wage, high-skill employment opportunities."
"The City of Coral Springs is excited to welcome Lupin," said City of Coral Springs Mayor Skip Campbell. "Our
community is well positioned to support world-class companies, like this one, and we look forward to playing a
role in their continued growth and success."
"Lupin’s grand opening in Broward County is an example of how our area is creating, attracting and expanding
high-wage jobs," said Bob Swindell, President and CEO of the Greater Fort Lauderdale Alliance. "The company’s
South Florida presence strengthens our state’s robust life sciences industry cluster and we wish them every
About Lupin Limited
Headquartered in Mumbai, Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of
branded and generic formulations as well as biotechnology products and APIs globally. The Company is a
significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space
and holds global leadership positions in the Anti-TB and Cephalosporin segment.
Lupin is the 5th largest and fastest growing top 5 generics player in the US (5.3% market share by prescriptions,
IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The Company is also amongst the top
10 generic pharmaceutical players in Japan and South Africa (IMS).
For the financial year ended 31st March 2015, Lupin's Consolidated turnover and Profit after Tax were 125,997 million (USD 2.06 billion) and 24,032 million (USD 393 million) respectively. Please visit http://www.lupin.com for more information.
About Aenova Group
The Aenova Group is one of the world’s largest providers of services covering the entire value chain for the
development and production of all the main dosage forms and product groups in the field of medicines and
dietary supplements. As the European business-to-business market leader, the Aenova Group focuses on high
standards of quality, innovative technologies and a clear vision for the future. The group operates overall 29
locations in eleven countries and employs more than 4700 people.
You could also follow us on Twitter – www.twitter.com/lupinlimited
CIN: L24100MH1983PLC029442 Registered Office: 159, C.S.T. Road, Kalina, Santacruz (East), Mumbai - 400 098.
For further information or queries please contact -
Head – Corporate Communications
Ph: +91-98 20 338 555
Head – M & A and Investor Relations
Ph: +91 98 20 023 511
Safe Harbor Statement